Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.
Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.
In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.
Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.
Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.
Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.
Liquidia Corporation (NASDAQ: LQDA) announced a significant market expansion for Treprostinil Injection due to the introduction of subcutaneous delivery, nearly doubling its addressable market. The company also resubmitted its NDA for LIQ861 (treprostinil) Inhalation Powder to the FDA, aiming for a six-month review. Financially, they improved their position with a private placement raising $21.7 million and new credit facilities. First-quarter revenue stood at $3.1 million compared to none last year, and a net loss of $9.2 million was reported.
Liquidia Corporation (NASDAQ: LQDA) has resubmitted its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH). The FDA issued a Complete Response Letter (CRL) in November 2020, citing incompleteness. Following a Type A meeting in January, the new NDA now includes additional chemistry and manufacturing details, but no new clinical data was required. The FDA plans to classify this resubmission as a Class 2, which entails a six-month review cycle. Liquidia is ready for required on-site inspections delayed by COVID-19.
Liquidia Corporation (NASDAQ: LQDA) will announce its first quarter 2021 financial results on May 13, 2021. The company will conduct a conference call at 8:30 a.m. EDT to discuss these results and provide a corporate update. Interested parties can join the call by dialing 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code: 2007727. The event will also be available via webcast on Liquidia's website, with an archive for later viewing.
Liquidia Corporation (NASDAQ: LQDA) announced a private placement agreement with accredited investors to sell 8,626,037 shares of common stock at $2.52 per share, raising approximately $21.7 million. The closing is set for today, with David Johnson from Caligan Partners LP joining the board. This funding aims to enhance commercial capabilities for LIQ861 and Treprostinil Injection, supporting growth initiatives. The company has agreed to file a registration statement to register the resale of shares within 180 days post-closing.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, from 1:30 to 2:10 p.m. EST. This event can be accessed via a live webcast on Liquidia's website, with a recorded version available for 90 days post-event. Liquidia focuses on pulmonary hypertension treatments and utilizes its PRINT® Technology for developing innovative products like LIQ861 and LIQ865.
Liquidia Corporation (LQDA) announced that the addressable market for generic Treprostinil Injection has more than doubled following FDA clearance of the RG 3ml Medication Cartridge for use with the CADD-MS® 3 pump. This breakthrough allows Treprostinil to be administered subcutaneously, expanding patient access for pulmonary arterial hypertension (PAH) treatment. The cartridge enables the first subcutaneous administration of the generic drug, previously limited to intravenous use.
Liquidia Corporation (NASDAQ: LQDA) reported its financial results for 2020, revealing a significant decrease in revenue to $0.7 million from $8.1 million in 2019. The company's net loss grew to $59.8 million, or $1.76 per share. Financial measures include a more than 40% reduction in annual cash spending planned for 2021, and a confirmed path to submit a response to the Complete Response Letter (CRL) for LIQ861 in mid-2021. Following the integration of RareGen, Liquidia aims to strengthen its commercial presence in pulmonary arterial hypertension (PAH). Cash reserves were at $65.3 million as of year-end 2020.
Liquidia Corporation (NASDAQ: LQDA) will announce its 2020 financial results on March 23, 2021, followed by a webcast and conference call at 8:30 a.m. ET. The call can be accessed via phone or through their website. Liquidia specializes in developing treatments for pulmonary hypertension and other applications using its PRINT technology. Its key product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management.
Liquidia Corporation (NASDAQ: LQDA) announced the closing of a debt facility with Silicon Valley Bank, providing up to $20.5 million in loans. The initial tranche of $10.5 million has been funded and used to retire existing debt, adding $1 million to Liquidia’s balance sheet. The second tranche of $5 million is contingent on FDA tentative approval for LIQ861 by June 30, 2022, and the final tranche is available upon full approval by December 31, 2022. The facility matures on September 1, 2024, with interest-only payments through March 31, 2023.
Liquidia Corporation (NASDAQ: LQDA) has appointed Damian deGoa as the new CEO, effective immediately, succeeding Neal F. Fowler, who has retired. DeGoa brings extensive healthcare experience, particularly in pulmonary arterial hypertension (PAH). Under his leadership, Liquidia aims to address regulatory concerns for LIQ861, a drug recently acquired from RareGen. The CEO's stock option grant includes 2 million shares, with specific vesting conditions tied to regulatory and commercial milestones.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's primary focus?
What is YUTREPIA?
What is PRINT® technology?
What products are in Liquidia’s pipeline?
How does Liquidia generate revenue?
What recent leadership changes have occurred at Liquidia?
What is the current status of YUTREPIA’s FDA approval?
What are the financial highlights for Liquidia?
What legal challenges has Liquidia faced?
How can I learn more about Liquidia Corporation?
